Unraveling the serotonin saga: from discovery to weight regulation and beyond - a comprehensive scientific review

Cell & Bioscience

Review

Shuzheng Fang¹  Kristine Conde²  Yong Xu³ 

[1] College of Art and Sciences, Washington University in St. Louis, St. Louis, MO, USA;USDA/ARS Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, USA;USDA/ARS Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, USA;Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, USA;Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, 77030, Houston, TX, USA;

关键词: Serotonin;    5-HT;    Dorsal Raphe Nucleus;    Obesity;    Appetite;    Weight-loss;   

DOI  :  10.1186/s13578-023-01091-7

 received in 2023-07-10, accepted in 2023-07-21,  发布年份 2023

来源: Springer

【 摘 要 】

The prevalence of obesity is rapidly increasing worldwide, while the development of effective obesity therapies lags behind. Although new therapeutic targets to alleviate obesity are identified every day, and drug efficacy is improving, adverse side effects and increased health risks remain serious issues facing the weight-loss industry. Serotonin, also known as 5-HT, has been extensively studied in relation to appetite reduction and weight loss. As a result, dozens of upstream and downstream neural targets of 5-HT have been identified, revealing a multitude of neural circuits involved in mediating the anorexigenic effect of 5-HT. Despite the rise and fall of several 5-HT therapeutics in recent decades, the future of 5-HT as a therapeutic target for weight-loss therapy looks promising. This review focuses on the history of serotonin, the state of current central serotonin research, previous serotonergic therapies, and the future of serotonin for treating individuals with obesity.

【 授权许可】

CC BY   
© Society of Chinese Bioscientists in America (SCBA) 2023

【 图 表 】

42490_2023_74_Article_IEq8.gif